THE LONG DAWN

Dispatches / Brain & nerves

Defending the mind

Remibrutinib cut relapses versus teriflunomide in two phase 3 multiple sclerosis trials

A new oral class against multiple sclerosis, tested on two thousand people across 46 countries.

Phase 3Peer-reviewed journal

What happened

  • REMODEL‑1 and REMODEL‑2 randomly assigned 2,007 people with relapsing MS to remibrutinib (a BTK inhibitor, Novartis) or teriflunomide, an existing oral drug.
  • Annual relapse rates were lower with remibrutinib: 0.073 versus 0.112, and 0.080 versus 0.116 (rate ratios 0.65 and 0.69). Published in The Lancet.
  • Fewer people stopped remibrutinib because of side effects (3.1% vs 5.8%), and the authors report no liver safety concerns.

What we don't know yet

  • The trials are ongoing; long-term disability results are not in yet.
  • It is not approved for MS. Comparison was with teriflunomide, not the strongest MS drugs.

Primary sources

Not medical advice. This is a summary of published results, not a recommendation. Ask your own doctor whether any treatment or trial fits you. To look for trials near you, search ClinicalTrials.gov or the WHO trial registry portal.